Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 24/10/2017

Debbie Rigby takes a look at the latest in research news Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations Onabotulinum toxin A (BoNT-A) is approved treatment for the prevention of chronic migraine. Its efficacy increases considerably over time during long-term treatments, significantly varying among patients. Short duration of migraine,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘We need more pharmacists’

You can't own a regional pharmacy and get PBS approval without living in the region. Problem solved.

Big Pharma

‘We need more pharmacists’

Hmmm…how could we possibly get more pharmacists to go rural…hmmm….oh wait! What’s that thing called again? You know…it starts with…

John Smith

‘We need more pharmacists’

I think we should do the same thing we do every time, let's flood the market with pharmacists, drive wages…

Evan Nickols

What does the future look like for CWH/Sigma shareholders?

But doesn’t this change as they slowly cripple their competition? It’s the classic Walmart move. Walk in, kill the competition…

John Smith

Research Roundup

Previous Government tactics under fire

Next Vaping nicotine linked to later smoking

Ceramides: what are they and why are they important?

In the beginning

The signs of ageing

Hyperpigmentation

MENU

Previous Government tactics under fire

Next Vaping nicotine linked to later smoking

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.